Carmela Caputo

Carmela Caputo


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2013 in Pituitary
Verified
Journal Article
Closed access
PDF file
CCCarmela Caputo
Carmela Caputo
ABAli Bazargan
Ali Bazargan
PMPenelope A. McKelvie
Penelope A. McKelvie
TSTom Sutherland
Tom Sutherland
CSCharles S. Su
Charles S. Su
WIWarrick J Inder
Warrick J Inder

1 November 2015 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
CCCarmela Caputo
Carmela Caputo
DPDavid Prior
David Prior
WIWarrick J Inder
Warrick J Inder

31 May 2017 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
AWAnna K. Watts
Anna K. Watts
AEAbhishek Easwaran
Abhishek Easwaran
PMPeter McNeill
Peter McNeill
YWYi Yuen Wang
Yi Yuen Wang
WIWarrick J Inder
Warrick J Inder
CCCarmela Caputo
Carmela Caputo

12 March 2013 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
CCCarmela Caputo
Carmela Caputo
TSTom Sutherland
Tom Sutherland
SFStephen Farish
Stephen Farish
PMPeter McNeill
Peter McNeill
KNKong W. Ng
Kong W. Ng
WIWarrick J Inder
Warrick J Inder

11 July 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
CCCarmela Caputo
Carmela Caputo
DPDavid Prior
David Prior
WIWarrick J Inder
Warrick J Inder
A decade on from the alarming association of cabergoline associated valvulopathy (CAV) in Parkinson’s disease, only 2 confirmed cases have occurred in prolactinoma patients. Routine screening for CAV by echocardiogram has not proven to be of diagnostic utility, has several limitations and is not widely practised. We have previously highlighted the value of annual cardiovascular examination as screening tool for CAV in prolactinoma patients. We present a case to highlight the value of the cardiovascular examination, which is now the third confirmed case of CAV. A 52 year old female with a 25 year history of macroprolactinoma had received multimodal treatment including surgery, radiosurgery and medical therapy. Her medical therapy initially consisted of bromocriptine followed by cabergoline. The cabergoline dose was 6mg weekly, and in 2009 the cumulative dose of 3272mg when an echocardiogram showed no evidence of valvular disease. A routine cardiovascular examination in clinic detected a new murmur in 2016. Echocardiogram demonstrated new onset mild- moderate aortic regurgitation, with a thickened and restricted valve consistent with CAV. Cumulative dose of cabergoline at this time was 4192mg. Follow up echocardiogram at six monthly intervals showed progression to moderate-severe aortic regurgitation, which has now stabilized. Cabergoline therapy was weaned and stopped completely in April 2017. Annual cardiovascular examination is the best screening test for CAV and can change the course of patient management. Echocardiograms should be reserved for patients with a new onset cardiac murmur or a high cumulative dose of cabergoline.

19 January 2009 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
TTTricia M. M. Tan
Tricia M. M. Tan
CCCarmela Caputo
Carmela Caputo
FMFrancesco Medici
Francesco Medici
APAlidz L. Pambakian
Alidz L. Pambakian
ADAnne Dornhorst
Anne Dornhorst
BKBernard Khoo
Bernard Khoo